<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>261-LOW-MOLECULAR-WEIGHT-HEPARINS-AND-RELATED-DRUGS-(PREVENTIVE-DOSES).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="LOW MOLECULAR WEIGHT HEPARINS AND RELATED DRUGS (PREVENTIVE DOSES)" code="B01AB-002" /></DRUG1>
<DRUG2>
<DRUG name="ACETYLSALICYLIC ACID" rxcui="1191">
<ATC code="A01AD05" />
<ATC code="B01AC06" />
<ATC code="N02BA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>The combination of medications acting at different levels of hemeostasis increases the risk of bleeding. Thus, with patients under 65 years of age, adding heparin or similar substances in preventive doses to acetylsalicylic acid, whatever the dosage, must be taken into account by maintaining clinical and possibly biological monitoring.</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>261-LOW-MOLECULAR-WEIGHT-HEPARINS-AND-RELATED-DRUGS-(PREVENTIVE-DOSES).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="LOW MOLECULAR WEIGHT HEPARINS AND RELATED DRUGS (PREVENTIVE DOSES)" code="B01AB-002" /></DRUG1>
<DRUG2>
<CLASS name="NON STEROIDAL ANTI-INFLAMMATORY DRUGS" code="M01A-002" /></DRUG2>
<DESCRIPTION>Increase of the risk of hemorrhage </DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
</INTERACTIONS>
